Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29469917 | 1.00 | NPSR1 (0.36) | NPSR1MAPTRXFP1PARP1RECQL | |
| SCHEMBL4647439 | 0.83 | NPSR1 (0.38) | NPSR1MAPTRXFP1PARP1RECQL | |
| SCHEMBL30016297 | 0.83 | PARP1 (0.37) | NPSR1MAPTRXFP1PARP1RECQL | |
| SCHEMBL21760974 | 0.83 | NPSR1 (0.36) | NPSR1MAPTRXFP1PARP1RECQL | |
| SCHEMBL29682808 | 0.81 | HTR3A (0.37) | MAPTPARP1 | |
| SCHEMBL21046810 | 0.81 | HTR3A (0.37) | MAPTPARP1 | |
| SCHEMBL31553890 | 0.80 | PARP1 (0.51) | PARP1NR3C1PGRNR3C2 | |
| SCHEMBL31172543 | 0.78 | PTGS1 (0.34) | MAPTPARP1 | |
| SCHEMBL31535705 | 0.78 | CYP2A6 (0.39) | MAPTPARP1 | |
| SCHEMBL16142977 | 0.77 | MAPT (0.37) | NPSR1MAPTRXFP1PARP1NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110452201-B | Synthetic method of benzofuran heterocyclic sulfonyl chloride | 泰州职业技术学院 | 2022-09-23 | — | — | CN | claimed |
| US-20260062393-A1 | Compounds | CTXT PTY LTD (AU) | 2026-03-05 | — | — | US | disclosed |
| US-12398097-B2 | WDR5-MYC inhibitors | VANDERBILT UNIVERSITY (US) | 2025-08-26 | — | — | US | disclosed |
| US-12365655-B2 | Compounds | CTXT PTY LTD (AU) | 2025-07-22 | — | — | US | disclosed |
| WO-2025100970-A1 | TNAP INHIBITORY COMPOUND AND USE THEREOF | 주식회사 레드엔비아 | 2025-05-15 | — | — | WO | disclosed |
| US-20240279207-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2024-08-22 | — | — | US | disclosed |
| EP-4335439-A2 | COMPOUNDS | CTXT PTY LTD (AU) | 2024-03-13 | — | — | EP | disclosed |
| EP-3810602-B1 | COMPOUNDS | CTXT PTY LTD (AU) | 2023-11-01 | — | — | EP | disclosed |
| EP-3810602-B1 | COMPOUNDS | CTXT PTY LTD (AU) | 2023-11-01 | — | — | EP | disclosed |
| EP-4229048-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | The Broad Institute, Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20080292585-A1 | Azonafide Derivatives, Methods for Their Production and Pharmaceutical Compositions Therefrom | UNIBIOSCREEN S.A. (BE) | 2008-11-27 | — | — | US | disclosed |
| US-20080293694-A1 | New compounds | BIOVITRUM AB (PUBL.) (SE) | 2008-11-27 | — | — | US | disclosed |
| EP-1981504-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES | NV Remynd (BE) | 2008-10-22 | — | — | EP | disclosed |
| WO-2008110598-A1 | TRICYCLIC ISOQUINOLINE DERIVATIVES FOR TREATMENT OF OBESITY | BIOVITRUM AB (PUBL) (SE) | 2008-09-18 | — | — | WO | disclosed |
| EP-1963255-A1 | SYNEPHRINE DERIVATIVES USEFUL AS ANTI-INFLAMMATORY AGENTS | UNIVERSITEIT GENT (BE) | 2008-09-03 | — | — | EP | disclosed |
| EP-1960365-A2 | AZONAFIDE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS THEREFROM | Unibioscreen S.A. (BE) | 2008-08-27 | — | — | EP | disclosed |
| WO-2008061781-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | NV REMYND (BE) | 2008-05-29 | — | — | WO | disclosed |
| WO-2007090617-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES | NV REMYND (BE) | 2007-08-16 | — | — | WO | disclosed |
| WO-2007071452-A1 | SYNEPHRINE DERIVATIVES USEFUL AS ANTI-INFLAMMATORY AGENTS | UNIVERSITEIT GENT (BE) | 2007-06-28 | — | — | WO | disclosed |
| WO-2007054292-A2 | AZONAFIDE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS THEREFROM | UNIBIOSCREEN S.A. (BE) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062393-A1 | Compounds | SCN2B, ABCB11, SCN1B | NPSR1 1018/4885MAPT 2629/4885RXFP1 360/4885 |
| US-20080293694-A1 | New compounds | HTR6, HTR1A, HTR1B | NPSR1 20/4885MAPT 1097/4885RXFP1 144/4885 |
| US-20240279207-A1 | SUBSTITUTED ACYL SULFONAMIDES FOR TREATING CANCER | KAT6A, KAT6B, KAT2A | NPSR1 3588/4885MAPT 4704/4885RXFP1 3249/4885 |
| US-20080292585-A1 | Azonafide Derivatives, Methods for Their Production and Pharmaceutical Compositions Therefrom | AADAC, NOTUM, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | NPSR1 4113/4885MAPT 2992/4885RXFP1 4803/4885 |
| US-12398097-B2 | WDR5-MYC inhibitors | MYC, WDR5, MYCBP | NPSR1 3979/4885MAPT 1222/4885RXFP1 4651/4885 |
| US-12365655-B2 | Compounds | SLC10A1, ABCB11, PCSK9 | NPSR1 401/4885MAPT 1136/4885RXFP1 2428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.